LEO Pharma's delgocitinib 20 mg/g cream demonstrated significant efficacy in Phase 3 DELTA TEEN study for adolescents aged 12-17 with chronic hand eczema.
Preliminary data from Cyclo Therapeutics' TransportNPC trial shows that 87% of patients under three years old with Niemann-Pick Disease Type C1 (NPC1) demonstrated stabilization or improvement after 24 weeks of Trappsol Cyclo treatment.
The FDA has approved two new treatments for Niemann-Pick Type C, a rare and fatal genetic disorder, marking a significant milestone for patients and families.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.